ArticleChemMedChem2012
Exhaustive fluorine scanning toward potent p53-Mdm2 antagonists.
Article in ChemMedChem, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Avoiding pitfalls when modelling ligands in macromolecular crystallography.Acta crystallographica. Section D, Structural biology · 2026Article
- Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries.European journal of medicinal chemistry · 2021Article
- Competition NMR for Detection of Hit/Lead Inhibitors of Protein-Protein Interactions.Molecules (Basel, Switzerland) · 2020Article
- Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives.Acta pharmaceutica Sinica. B · 2020Review
- Recent Small-Molecule Inhibitors of the p53-MDM2 Protein-Protein Interaction.Molecules (Basel, Switzerland) · 2020Review
- Controlling the stereochemistry in 2-oxo-aldehyde-derived Ugi adducts through the cinchona alkaloid-promoted electrophilic fluorination.Beilstein journal of organic chemistry · 2020Article
- A fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53The FEBS journal · 2019Article
- Structure and Reactivity of Glycosyl Isocyanides.European journal of organic chemistry · 2019Article
- Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists.Beilstein journal of organic chemistry · 2019Article
- The Catalytic Enantioselective Ugi Four-Component Reactions.Angewandte Chemie (International ed. in English) · 2018Review
- Artificial Macrocycles.Synlett : accounts and rapid communications in synthetic organic chemistry · 2018Article
- Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure-based virtual screening.Drug design, development and therapy · 2018Article
- Artificial Macrocycles as Potent p53-MDM2 Inhibitors.ACS medicinal chemistry letters · 2017Article
- Article
- Chemical Variations on the p53 Reactivation Theme.Pharmaceuticals (Basel, Switzerland) · 2016Review
- How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.ChemMedChem · 2016Review
- Discovery of a Potent Allosteric Kinase Modulator by Combining Computational and Synthetic Methods.Angewandte Chemie (International ed. in English) · 2015Article
- Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.Journal of medicinal chemistry · 2015Review
- Focusing on shared subpockets - new developments in fragment-based drug discovery.Expert opinion on drug discovery · 2015Review
- Fragment-based library generation for the discovery of a peptidomimetic p53-Mdm4 inhibitor.ACS combinatorial science · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.